DUP 129
Latest Information Update: 15 Jan 2008
At a glance
- Originator Bristol-Myers Squibb
- Class Antihyperlipidaemics
- Mechanism of Action Sterol O-acyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 01 Jun 1999 No-Development-Reported for Hypercholesterolaemia in USA (Unknown route)